A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients-Reference-Cited by-同舟云学术

A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients

Published:2010-05-18 Issue:2 Volume:122 Page:429-437
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Pierga Jean-Yves,Delaloge Suzette,Espié Marc,Brain Etienne,Sigal-Zafrani Brigitte,Mathieu Marie-Christine,Bertheau Philippe,Guinebretière Jean Marc,Spielmann Marc,Savignoni Alexia,Marty Michel

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-010-0939-3.pdf

Reference42 articles.

1. Jones RL, Smith IE (2006) Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response. Lancet Oncol 7:869–874

2. Untch M, von Minckwitz G (2009) Recent advances in systemic therapy. Advances in neoadjuvant (primary) systemic therapy with cytotoxic agents. Breast Cancer Res 11:203

3. Kaufmann M, von Minckwitz G, Bear HD, Buzdar A, McGale P, Bonnefoi H, Colleoni M, Denkert C, Eiermann W, Jackesz R, Makris A, Miller W, Pierga JY, Semiglazov V, Schneeweiss A, Souchon R, Stearns V, Untch M, Loibl S (2007) Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 18:1927–1934

4. Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G, Buzdar AU, Smith IE, Symmans WF, Singh B, Winer EP (2008) Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol 26:814–819

5. Mauri D, Pavlidis N, Ioannidis JP (2005) Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 97:188–194

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Racial and Ethnic Disparities in European Breast Cancer Clinical Trials;Cancers;2024-04-29

2. Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial;Breast Cancer Research and Treatment;2024-03-07

3. An inflamed tumor cell subpopulation promotes chemotherapy resistance in triple negative breast cancer;Scientific Reports;2024-02-14

4. Harnessing the synergistic potential of NK1R antagonists and selective COX-2 inhibitors for simultaneous targeting of TNBC cells and cancer stem cells;Journal of Drug Targeting;2024-02

5. Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level;British Journal of Cancer;2023-09-22